AirSculpt Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $193.3M
- Price
- $2.74
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.62%
- Volume
- 662.1K
About
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient’s own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company’s body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
Quick stats
Shares outstanding70.5M
Computed float17.0M
Float / shares24.1%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001870940
Websitehttp://www.airsculpt.com
AI Summary
AI-generated1/13
standardbearishearnings
AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results
AirSculpt Technologies reported Q2 fiscal 2026 revenue of $42.9 million, a 3% decline from the prior year, with Adjusted EBITDA falling to $4.9 million from $5.8 million.
The company reaffirmed its full-year revenue guidance at the lower end of the $151 million to $157 million range but reduced its Adjusted EBITDA outlook to $12 million to $14 million.
Liquidity improved during the quarter, with cash increasing to $18.8 million and gross debt decreasing to $44.2 million, supported by an amended term loan that extends maturity to November 2027.
Red flags
- Adjusted EBITDA outlook reduced to range of $12-$14 million
- Q2 revenue declined 3% year-over-year